Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Nemus Bioscience
Nemus Bioscience
Activities:
Ingredients
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Ingredients
Nemus and Pharmaceuticals International look to THC
Companies have agreed to develop a sterile eye drop dosage formulation, based on a cannabinoid, for Glaucoma
Drug Delivery
Suppository formulation of THC prodrug in development
The new human dosage formulation development will be used to manage chemotherapy-induced nausea
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
High hopes for cannabis
Cannabis has a long history of therapeutic as well as recreational use. Dr Sarah Houlton considers the properties that are making it increasingly attractive to pharma companies now that its legalisation is accelerating
Subscribe now